Publications

The poster presents a functional combinatorial precision medicine platform, Optim.AI™, designed to predict the efficacy of immunotherapy combinations in breast cancer. It addresses the limitations of current ex vivo models in accurately representing the tumor microenvironment and predicting patient-specific responses. By combining 3D tumor-immune cell co-culture with high-content imaging and Optim.AI™ analysis, this research offers a promising approach for evaluating immunotherapy-focused drug sets in HER2-positive and triple-negative breast cancer subtypes.